552-12-5

Basic information

• Product Name: GALACTURONIC ACID
• CAS NO: 552-12-5
• Molecular Formula: C₆H₁₀O₇
• Molecular Weight: 0
• Mol File: 552-12-5.mol
• Article Data: 145

Chemical Properties

• Appearance: /
• CAS DataBase Reference: GALACTURONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: GALACTURONIC ACID(552-12-5)
• EPA Substance Registry System: GALACTURONIC ACID(552-12-5)

Safety Data

• Hazardous Substances Data: 552-12-5(Hazardous Substances Data)

Upstream product

• 40386-94-5 α-D-GalpA-(1->4)-α-D-GalpA-(1->4)-α-D-GalpA-(1->4)-α-D-GalpA-(1->4)-D-GalpA 
• 40386-95-6 α-D-GalpA-(1->4)-α-D-GalpA-(1->4)-α-D-GalpA-(1->4)-α-D-GalpA-(1->4)-α-D-GalpA-(1->4)-D-GalpA 
• 40307-14-0 α-D-GalpA-(1->4)-α-D-GalpA-(1->4)-α-D-GalpA-(1->4)-D-GalpA 
• 40307-13-9 tri-galacturonic acid 
• 73977-52-3 2,4-di-O-acetyl-β-methyl-D-galactopyranosideuronic acid γ-lactone 
• 6294-16-2 D-galacturonic acid 
• 902141-54-2 di(D-galactosiduronic) acid 
• 18486-47-0 methyl D-galactopyranuronate 
• 56317-11-4 apigenin 7-O-β-D-galacturonopyranoside 
• 56324-53-9 luteolin-7-O-β-D-galacturonide 
• 488148-26-1 chrysin-7-O-β-D-galacturonide 
• 186581-53-3 diazomethane 
• 107091-09-8 3-O-β-D-galactopyranosyl-(1->2)-<β-D-xylopyranosyl-(1->3)>-β-D-glucuronopyranosyl quillaic acid 28-O-β-D-apiofuranosyl-(1->3)-β-D-xylopyranosyl-(1->4)-<β-D-glucopyranosyl-(1->3)>-α-L-rhamnopyranosyl-(1->2)-β-D-fucopyranoside. 
• 17685-07-3 O¹-Propyl-β-D-glucopyranuronsaeure 

Downstream Products

• 5155-54-4 methyl (methyl α-D-galacturonopyranoside)uronate 
• 18486-38-9 methyl β-D-glucuronopyranoside methyl ester 
• 133640-39-8 methyl α,β-D-glucopyranosidurono-6,3-lactone 
• 17681-01-5 methyl β-D-glucofuranosidurono-6,3-lactone 
• 17681-01-5 methyl α-D-glucofuranosidurono-6,3-lactone 
• 18486-51-6 1-O-methyl-α-D-glucopyranuronic acid methyl ester 
• 110-00-9 furan 
• 98-01-1 furfural 
• 141-46-8 Glycolaldehyde 
• 67-64-1 acetone 
• 87-73-0 D-glucaric acid 
• 499-05-8 comanic acid 
• 95722-14-8 1,2,3-tri-O-acetyl-4-deoxy-β-L-threo-4-hexenopyranuronic acid 
• 7251-61-8 2-methylquinoxaline 

Relevant articles and documents

Application of bacterial directed enzyme prodrug therapy as a targeted chemotherapy approach in a mouse model of breast cancer

Cancer is the second leading cause of death in the world. Some of the usual cancer treatments include surgery, chemotherapy, and radiotherapy. However, due to low efficacy and side effects of these treatments, novel targeted therapeutic methods are needed. One of the common drawbacks of cancer chemotherapy is off-target toxicity. In order to overcome this problem, many investigations have been conducted. One of the new targeted therapy methods known as bacterial directed enzyme-prodrug therapy (BDEPT) employs bacteria as enzyme carriers to convert a pro-drug to a drug specifically within the tumor site. In the present study, we used Escherichia coli DH5α carrying luxCDABE gene cluster and overexpressing β-glucuronidase for luminescent emission and enzyme expression, respectively. Enzyme expression can lead to the conversion of glycyrrhizic acid as a prodrug to glycyrrhetinic acid, a potent anti-cancer agent. DH5α-lux/βG was characterized and its stability was also evaluated. Bacteria colonization in the tumor site was measured by tissue homogenate preparation and colony counting method. Histopathological studies on the liver, spleen, and tumor were also conducted. According to the results, co-treatment of 4T1, a highly metastatic mouse breast cancer cell line, with GL and DH5α-lux/βG could significantly decrease the IC50 values. Moreover, increased number of bacteria could lead to a dramatic drop in IC50 value. Specific colonization of DH5α-lux/βG was observed in the tumor site compared with other tissues (p 0.0001). Moreover, the biocompatibility evaluation proved that DH5α-lux/βG had no adverse effects on normal tissues. Furthermore, concurrent usage of GL and bacteria in the treatment of induced 4T1 tumors in BALB/c mice significantly delayed tumor growth (p0.001) during 16 days of investigation. Based on these findings, BDEPT might be useful for targeted breast cancer therapy, although further investigations are required to confirm this.

A Reusable Column Method Using Glycopolymer-Functionalized Resins for Capture–Detection of Proteins and Escherichia coli

The use of glycopolymer-functionalized resins (Resin–Glc), as a solid support, in?column mode for bacterial/protein capture and quantification is explored. The Resin–Glc is synthesized?from commercially available chloromethylated polystyrene?resin and glycopolymer, and is characterized by fourier transform infrared spectroscopy, thermogravimetry, and elemental analysis. The percentage of glycopolymer functionalized on Resin–Glc is accounted to be 5 wt%. The ability of Resin–Glc to selectively capture lectin, Concanavalin A, over Peanut Agglutinin, reversibly, is demonstrated for six cycles of experiments. The bacterial sequestration study using SYBR (Synergy Brands, Inc.) Green I tagged?Escherichia coli/Staphylococcus aureus?reveals the ability of Resin–Glc to selectively capture?E. coli?over?S. aureus. The quantification of captured cells in the column is carried out by enzymatic colorimetric assay using methylumbelliferyl glucuronide?as the substrate. The?E. coli?capture studies reveal a consistent capture efficiency of 105?CFU (Colony Forming Units) g?1 over six cycles. Studies with spiked tap water samples show satisfactory results for?E. coli?cell densities ranging from 102 to 107?CFU mL?1. The method portrayed can serve as a basis for the development of a reusable solid support in capture and detection of proteins and bacteria.

Isolation and identification of two new sargentodoxosides from Sargentodoxa cuneata and their agonistic effects against FXR

Sargentodoxa cuneata (Oliv.) Rehd. et Wils is a traditional Chinese medicine to treat acute appendicitis, rheumarthritis, abdominal pain, and painful menstruation for a long history. The investigation of S. cuneata led to the isolation and identification of twenty-three secondary metabolites, including two new compounds, sargentodoxosides A (1) and B (2), and twenty-one known ones (3-23). Their structural characterization was conducted by HRESIMS, 1 D and 2 D NMR spectra. All the isolated compounds were assayed for their agonistic activities against the farnesoid X receptor (FXR). Nine of the isolated compounds displayed significant agonistic effects against FXR at 0.1 μM, suggesting that they could be served as potential agents for the development of FXR agonists.